title: Clinicopathological Study of 30 Cases of Peripheral T-cell Lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan.
abstract: The presence of Hodgkin and Reed-Sternberg (HRS)-like B-cells in peripheral T-cell lymphoma (PTCL) is rare and its clinicopathological features still remain unclear. Here, we describe 30 cases of PTCL with HRS-like B-cells from Japan. Twenty-three cases (77%) presented evidence of follicular T-helper phenotype (TFH) derivation: 12 were angioimmunoblastic T-cell lymphoma and 11 PTCL with TFH phenotype (PTCL-TFH). The remaining seven cases were diagnosed as PTCL, not otherwise specified (PTCL-NOS). Epstein-Barr virus (EBV) reactivation was detected in 25 cases (83%), but HRS-like B-cells were EBER in only 20 cases (67%). The median age at diagnosis was 77 years (range, 39-91 y), including 24 patients (80%) were older than 60 years of age. Most of the patients presented at an advanced clinical stage and were associated with higher risk according to the International Prognostic Index. The 3-year overall and progression-free survival rates were 44% and 27%, respectively. No significant clinicopathological differences were detected between PTCL-TFH, PTCL-NOS and the angioimmunoblastic cases. Cases with EBER HRS-like B-cells were associated with inferior overall and progression-free survival compared to those with EBER HRS-like B-cells, but the difference was not significant. In conclusion, HRS-like B-cells were found in a subset of T-cell lymphomas, especially in association with the TFH phenotype and EBV reactivation. These cells have a tendency to affect elderly patients and to be associated with advanced clinical stages and dismal prognosis. The EBV status of HRS-like B-cells does not seem to affect the clinicopathological features of this group of PTCLs.
authors.affiliation: *Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan †Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura, Egypt ‡Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan §Department of Clinical Laboratory, Nagano Prefectural Suzaka Hospital, Nagano, Japan.
authors.forename: Ahmed E
authors.initials: AE
authors.lastname: Eladl
authors.forename: Akira
authors.initials: A
authors.lastname: Satou
authors.forename: Ahmed Ali
authors.initials: AA
authors.lastname: Elsayed
authors.forename: Yuka
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Seiichi
authors.initials: S
authors.lastname: Kato
authors.forename: Naoko
authors.initials: N
authors.lastname: Asano
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000276:immunology / Q000473:pathology* / Q000821:virology; D060890:B7-H1 Antigen / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D001706:Biopsy; D018572:Disease-Free Survival; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000276:immunology / Q000473:pathology* / Q000628:therapy / Q000821:virology; D007150:Immunohistochemistry; D007564:Japan; D053208:Kaplan-Meier Estimate; D016411:Lymphoma, T-Cell, Peripheral / Q000276:immunology / Q000473:pathology* / Q000628:therapy / Q000821:virology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010641:Phenotype; D012367:RNA, Viral / Q000235:genetics; D016539:Reed-Sternberg Cells / Q000276:immunology / Q000473:pathology* / Q000821:virology; D012307:Risk Factors; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology / Q000473:pathology* / Q000821:virology; D013997:Time Factors; D016896:Treatment Outcome; D014775:Virus Activation
chemical_list: D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; D012367:RNA, Viral